Is Iovance Biotherapeutics a Buy?
Cell therapies are increasingly being added to drug pipelines across the biopharmaceutical industry, but Iovance Biotherapeutics (NASDAQ: IOVA) was one of the first movers with its tumor-infiltrating lymphocytes (TILs). In fact, the company is likely to earn marketing approval for two drug candidates in 2021.
The upcoming transition to commercial operations is a big milestone for the business and shareholders, especially if revenue ramps to levels that allow for operating income and positive cash flow. While the biotech stock has performed relatively well in 2020, some of the excitement has waned. Investors initially hoping for an acquisition have come to acknowledge recent moves suggest Iovance Biotherapeutics plans on remaining a stand-alone company.
Given all of the moving parts, is this biopharma stock a buy?
Source Fool.com
